Gene therapy for progressive familial intrahepatic cholestasis type 3 in a clinically relevant mouse model
Progressive familial intrahepatic cholestasis type 3 is a disease caused by mutations in the gene encoding the multidrug resistance protein 3, and has limited treatment options. Here they show that adeno-associated virus mediated gene therapy prevents disease progression in a mouse disease model.
Guardado en:
Autores principales: | Nicholas D. Weber, Leticia Odriozola, Javier Martínez-García, Veronica Ferrer, Anne Douar, Bernard Bénichou, Gloria González-Aseguinolaza, Cristian Smerdou |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2019
|
Materias: | |
Acceso en línea: | https://doaj.org/article/01e5e4ee2f0f4ae9875e80c35af9e27b |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Progressive familial intrahepatic cholestasis: diagnosis, management, and treatment
por: Gunaydin M, et al.
Publicado: (2018) -
Mutations in the nuclear bile acid receptor FXR cause progressive familial intrahepatic cholestasis
por: Natalia Gomez-Ospina, et al.
Publicado: (2016) -
A homozygous R148W mutation in Semaphorin 7A causes progressive familial intrahepatic cholestasis
por: Qiong Pan, et al.
Publicado: (2021) -
Progressive familial intrahepatic cholestasis type 3: Report of four clinical cases, novel ABCB4 variants and long-term follow-up
por: Patryk Lipiński, et al.
Publicado: (2021) -
Evaluation of FGF-19 and β-klotho as biomarkers in patients with intrahepatic cholestasis of pregnancy
por: Ahter Tanay Tayyar, et al.
Publicado: (2018)